Ozempic Conditions: The Indications It Is Approved For

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

An indications overview from the PlexusDx Education Hub, organized around the conditions GLP-1 medications are approved to treat.

When people search "Ozempic conditions," they usually want the list of what it and its class are FDA-approved for, plus enough context to understand the mechanism behind those approvals. This overview leads with the indications, then covers how the medication works, its side effects, and the cost landscape. Figures reflect April 2026, and qualitative facts stay qualitative.

Framing it around indications first is deliberate, since the most common source of confusion is assuming that an approval attached to one brand automatically extends to every use of the same molecule, when coverage and prescribing actually track the specific label in front of them.

The FDA-approved indications

Across the GLP-1 class, FDA-approved indications include type 2 diabetes for most compounds, chronic weight management for Wegovy, Saxenda, and Zepbound, cardiovascular risk reduction in type 2 diabetes for several products, and obstructive sleep apnea in adults with obesity for Zepbound as of 2024. Prescribing matches each brand's approved indication rather than the molecule alone.

What Ozempic is

Ozempic is Novo Nordisk's brand of semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes. The same molecule is marketed as Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Semaglutide is engineered from native human GLP-1 to resist DPP-4 degradation, sustaining receptor engagement at therapeutic doses.

How the mechanism produces those uses

GLP-1 receptor agonists engage receptors in the pancreas, hypothalamus, and gastrointestinal tract, slowing gastric emptying, blunting post-meal glucose excursions, reducing appetite, and raising satiety signaling. Those actions underpin the diabetes and weight indications. GIP/GLP-1 dual agonists like tirzepatide add GIP-receptor engagement, a second incretin mechanism. Dosing is weekly or daily depending on the compound.

Side effects across the class

Gastrointestinal symptoms, nausea, vomiting, diarrhea, and constipation, are the most reported and usually most pronounced during titration. Every FDA-approved GLP-1 compound carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Rarer serious events include pancreatitis, gallbladder disease, and acute kidney injury tied to dehydration.

Cost and access in brief

Manufacturer list prices for FDA-approved branded products typically run $800 to $1,600 per month at U.S. list as of April 2026. Out-of-pocket cost hinges on coverage, the indication on the prescription, savings-card eligibility, and whether a compounded 503A pathway applies. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

Genetics beneath the indications

The conditions on a label describe approvals, not the individual biology a person brings to treatment. Variants in GLP1R, the receptor gene, and TCF7L2, linked to glucose homeostasis, shape metabolic terrain. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights as trait education. It never predicts drug response, serving as context for a provider discussion.

On-label prescribing and clinical judgment

The indications listed on a label define the uses a manufacturer has secured FDA approval for, and prescribing generally follows those approved uses. This is why the same molecule can be covered for one condition under one brand and for a different condition under another, with coverage logic tracking the specific label rather than the ingredient.

Clinical practice can be more nuanced than a label list suggests, since a provider weighs an individual's full history, contraindications, and goals when deciding what is appropriate. That evaluation is where the abstract indication meets the concrete patient. For someone researching which conditions a GLP-1 medication addresses, the practical point is that the label answers what a product is approved for, while a qualified clinician determines whether it fits a particular person. Both pieces matter, and neither substitutes for the other. Keeping them distinct avoids the common mistake of assuming that an approval for one brand automatically transfers to every situation involving the same molecule.

Frequently Asked Questions

What conditions is Ozempic approved to treat?

Ozempic itself is FDA-approved for type 2 diabetes. Across the broader GLP-1 class, approved indications include chronic weight management for certain brands, cardiovascular risk reduction in type 2 diabetes for several products, and obstructive sleep apnea in adults with obesity for Zepbound as of 2024. Prescribing follows each brand's label.

Why does the same molecule have different indications?

Manufacturers pursue separate FDA approvals for the same active ingredient under different brands, so semaglutide is approved for diabetes as Ozempic and for weight management as Wegovy. Coverage and prescribing follow the brand's specific indication, which is why one molecule can appear under multiple labels with distinct approved uses.

What are the main risks to know?

Gastrointestinal side effects are most common, especially during titration. The GLP-1 class carries a boxed warning for thyroid C-cell tumor risk observed in rodents, and it is contraindicated with certain thyroid cancer histories. Rare serious events include pancreatitis and gallbladder disease. Discuss your full history with a provider.

Does genetic testing diagnose these conditions?

No. The Precision Peptide Genetic Test does not diagnose disease or predict drug response. It analyzes pathway variants in genes such as GLP1R and TCF7L2 that shape baseline glucose and appetite biology, offering upstream context to bring into a conversation with a qualified healthcare provider rather than a diagnosis.

Continue exploring indications and mechanism articles at the PlexusDx Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.